Kobo Biotech Ltd.
Snapshot View

6.78 -0.35 ▼-4.9%

26 July 2021, 04:00:00 P.M.
Volume: 2,870

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.avonorganicsltd.com
Financial Indicators
Market Cap 16.15 Cr.
Earnings per share (EPS) -8.07 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share -45.00 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.15 Calculated using Price: 6.78
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.38 Cr. 23,825,000 Shares
FaceValue 10
Company Profile

AVON Organics Limited (AOL) was started by P R Agarwal, Rajesh Agarwal along with late G S Sidhu .It is located at Madhupala Towers Greenlands, Hyderabad 500 016, India. The company's transition from a machinery manufacturer to a full-fledged chemical manufacturer saw the company foraying into the highly technology-intensive area of Diketene and its derivatives.

In the year 1996 the company established and successfully commissioned its first grass root Diketene plant .It has doubled its production capacity by commissioning an additional 1000 TPA unit as part of its second phase in 1998.  It is an ISO 9000 certification by the Lloyds Register Quality Assurance (LRQA).

Business profile:

A keen insight and a well-planned development process saw AOL discover the opportunity in the production of Diketene - the basic unit for hundreds of derivatives in pesticides, chemicals, pharmaceuticals and dyestuffs. A highly classified technology, it has been sourced from Shanghai Peng Pu Chemical Works, China, and Xytel Technology Partnership, USA, and now rests in the hands of a few chosen manufacturers across the globe.

The company, with its immense infrastructure framework has introduced modifications to the Chinese technology and has a current production of 3000 tonnes per annum against an installed capacity of 2000 tonnes per annum. A sprawling facility of 21 acres, the plant is situated 60 kilometers from Hyderabad. The locale is ideal due to its easy connectivity made possible by the well-traversed National Highway # 9 that links Hyderabad with Mumbai.

Products :

  • Diketene:
  • Pharmaceutical intermediates
  • Agrochemical intermediates
  • Pigment intermediates 

Pharmaceutical (Including Ephedrines) :

  • Active Pharmaceutical ingredients
  • Pharma intermediates
  • Formulation intermediates 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.91%
1 Week
-2.59%
1 Month
+23.27%
3 Month
+10.06%
6 Month
+23.05%
1 Year
+72.96%
2 Year
+189.74%
5 Year
-23.91%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 15.45 11.33 -53.52 -103.90 -233.98
Return on Capital Employed (%) 16.28 13.15 -7.12 -8.67 -1.32 -2.78 -5.12 -5.74 -3.93
Return on Assets (%) 3.97 3.09 -11.70 -11.40 -6.43 -7.50 -9.60 -10.08 -8.83

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 69 77 45 14 6 -19 -43 -67 -88
Non Curr. Liab. 85 67 79 74 74 64 47 40 40
Curr. Liab. 103 133 155 164 180 207 242 266 284
Minority Int.
Equity & Liab. 258 278 279 252 260 252 246 239 236
Non Curr. Assets 124 123 118 110 102 95 89 83 77
Curr. Assets 133 155 161 142 158 157 157 157 159
Misc. Exp. not W/O
Total Assets 258 278 279 252 260 252 246 239 236

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 167 170 57 29 33
Other Income 0 0 3 1 1 6 0 1 2
Total Income 167 170 60 30 34 6 0 1 2
Total Expenditure -126 -134 -64 -39 -29 -4 -3 -3 -3
PBIDT 42 36 -4 -9 5 2 -3 -2 -1
Interest -20 -17 -18 -16 -14 -14 -15 -14 -14
Depreciation -11 -10 -10 -8 -7 -7 -6 -6 -6
Taxation -1 -1 -1
Exceptional Items 3 -2
PAT 10 8 -33 -30 -16 -19 -24 -24 -21

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 58 38 11 19 6 32 31 21 14
Cash Fr. Inv. -25 -8 -5
Cash Fr. Finan. -27 -36 -7 -21 -5 -33 -31 -21 -14
Net Change 5 -6 -1 -1 0 0
Cash & Cash Eqvt 8 2 1 0 1 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 44.95 44.95 44.95 44.95 44.95 44.95 44.95 44.95 44.95
Public 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
We are enclosing herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30th June 2021 received from XL Softech Systems Ltd Registrar and Share Transfer Agent of our Company.
Mon, 19 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- JIGNESH PATEL
Designation :- Company Secretary and Compliance Officer
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Kobo Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Stochastic Reversing from Overbought Zone Stochastic Reversing from Overbought Zone
Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%